Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.37 |
| ▸ | HTR2B | P41595 | 10/20 | 0.37 |
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769202 | 0.85 | HTR2C (0.36) | HTR2CHTR2BHTR2ABACE1AKT1 | |
| SCHEMBL3759177 | 0.84 | POLB (0.35) | MAPK1 | |
| SCHEMBL4738514 | 0.83 | HTR2A (0.34) | HTR2CHTR2BHTR2AGPR119MAPK1 | |
| SCHEMBL3769425 | 0.81 | HTR2A (0.46) | HTR2CHTR2BHTR2ABACE1 | |
| SCHEMBL1852427 | 0.80 | TACR1 (0.33) | — | |
| SCHEMBL6992310 | 0.79 | HTR2C (0.39) | HTR2CHTR2BHTR2ASMARCA2SMARCA4 | |
| SCHEMBL3998042 | 0.79 | HTR2C (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL4133764 | 0.77 | HTR2C (0.36) | HTR2CHTR2BHTR2AMAPK1 | |
| SCHEMBL1852426 | 0.76 | HTR2C (0.34) | HTR2CHTR2BHTR2AGPR119 | |
| SCHEMBL828122 | 0.74 | HTR2C (0.42) | HTR2CHTR2BHTR2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | HTR2C 1741/4885HTR2B 2122/4885HTR2A 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.